These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6341912)

  • 21. ICRF-159 versus polychemotherapy in non-small cell lung cancer.
    Eagan RT; Carr DT; Coles DT; Rubin J; Frytak S
    Cancer Treat Rep; 1976 Jul; 60(7):947-8. PubMed ID: 64297
    [No Abstract]   [Full Text] [Related]  

  • 22. A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma.
    Bellet RE; Catalano RB; Danna VG; Berd DA; Berkelhammer J; Mastrangelo MJ
    J Clin Pharmacol; 1976; 16(8-9):433-8. PubMed ID: 787016
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
    Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
    Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
    Bakowski MT
    Cancer Treat Rev; 1976 Jun; 3(2):95-107. PubMed ID: 821609
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
    Bellet RE; Engstrom PF; Catalano RB; Creech RH; Mastrangelo MJ
    Cancer Treat Rep; 1976 Sep; 60(9):1395-7. PubMed ID: 1016973
    [No Abstract]   [Full Text] [Related]  

  • 26. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of blast cell crisis of chronic myeloid leukemia with ICRF-159 (razoxane).
    Bakowski MT; Brearley RL; Wrigley PF
    Cancer Treat Rep; 1979; 63(11-12):2085-7. PubMed ID: 294308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.
    Dyment PG; Starling KA; Land VJ; Cangir A; Komp DM; Sexauer CL
    Cancer Treat Rep; 1979 Aug; 63(8):1397-8. PubMed ID: 476712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
    Liesmann J; Belt R; Haas C; Hoogstraten B
    Cancer; 1981 Apr; 47(8):1959-62. PubMed ID: 6784914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.
    Gilbert JM; Hellmann K; Evans M; Cassell PG; Stoodley B; Ellis H; Wastell C
    Cancer Chemother Pharmacol; 1982; 8(3):293-9. PubMed ID: 7127660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of ICRF-159 in refractory metastatic breast cancer.
    Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
    Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADR-529 (ICRF-187).
    Cancer Invest; 1989; 7(1):101. PubMed ID: 2500223
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
    Ryall RD; Bates T; Newton KA; Hellmann K
    Cancer; 1979 Sep; 44(3):891-5. PubMed ID: 113077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Radio-oncological treatment possibilities in local recurrence of rectal carcinoma. An interdisciplinary comparison].
    Rhomberg W; Eiter H
    Wien Med Wochenschr; 1990 Apr; 140(8):206-11. PubMed ID: 2194376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Razoxane (ICRF 159) in the treatment of psoriasis.
    Atherton DJ; Wells RS; Laurent MR; Williams YF
    Br J Dermatol; 1980 Mar; 102(3):307-17. PubMed ID: 7370178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial.
    Zuliani AC; Esteves SC; Teixeira LC; Teixeira JC; de Souza GA; Sarian LO
    J Clin Oncol; 2014 Feb; 32(6):542-7. PubMed ID: 24449243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of stage IIIB cervical carcinoma. A comparison between radiotherapy, concurrent chemo-radiotherapy and neoadjuvant chemotherapy].
    Maneo A; Colombo A; Landoni F; Colombo A; Villa A; Mangioni C
    Minerva Ginecol; 2005 Apr; 57(2):141-52. PubMed ID: 15940074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical evaluation of ICRF 159 as a radiosensitising agent.
    Bates T
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
    [No Abstract]   [Full Text] [Related]  

  • 39. ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Conroy J; Hatch K; DiSaia PJ; Twiggs LB
    Am J Clin Oncol; 1986 Feb; 9(1):15-7. PubMed ID: 3953488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
    Vogl SE; Lanham R; Kaplan BH
    Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.